Equity Analysis /
United States of America

US : ADMA Biologics, Inc. - ADMA | 2Q22 Financials: Out For Blood - Sequential Top Line Progression Supports Key Revenue Targets

    Michael Parolari
    Michael Parolari

    Research Associate

    Follow
    CGS-CIMB
    11 August 2022
    Published byCGS-CIMB